170 related articles for article (PubMed ID: 33248001)
1. Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: Effect of interleukin 6-induced suppression of the cytochrome P450 3A gene.
Enokiya T; Nishikawa K; Hamada Y; Ikemura K; Sugimura Y; Okuda M
Basic Clin Pharmacol Toxicol; 2021 Mar; 128(3):525-533. PubMed ID: 33248001
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients.
Barry A; Levine M
Ther Drug Monit; 2010 Dec; 32(6):708-14. PubMed ID: 20864901
[TBL] [Abstract][Full Text] [Related]
3. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
4. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.
Vanhove T; de Jonge H; de Loor H; Annaert P; Diczfalusy U; Kuypers DR
Br J Clin Pharmacol; 2016 Dec; 82(6):1539-1549. PubMed ID: 27501475
[TBL] [Abstract][Full Text] [Related]
5. A Minimal Physiologically-Based Pharmacokinetic Model for Tacrolimus in Living-Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype.
Itohara K; Yano I; Tsuzuki T; Uesugi M; Nakagawa S; Yonezawa A; Okajima H; Kaido T; Uemoto S; Matsubara K
CPT Pharmacometrics Syst Pharmacol; 2019 Aug; 8(8):587-595. PubMed ID: 31087501
[TBL] [Abstract][Full Text] [Related]
6. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.
Glowacki F; Lionet A; Hammelin JP; Labalette M; Provôt F; Hazzan M; Broly F; Noël C; Cauffiez C
Clin Pharmacokinet; 2011 Jul; 50(7):451-9. PubMed ID: 21528942
[TBL] [Abstract][Full Text] [Related]
7. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
Bruckmueller H; Werk AN; Renders L; Feldkamp T; Tepel M; Borst C; Caliebe A; Kunzendorf U; Cascorbi I
Ther Drug Monit; 2015 Jun; 37(3):288-95. PubMed ID: 25271728
[TBL] [Abstract][Full Text] [Related]
8. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients.
Uesugi M; Hosokawa M; Shinke H; Hashimoto E; Takahashi T; Kawai T; Matsubara K; Ogawa K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Biol Pharm Bull; 2013; 36(11):1814-21. PubMed ID: 24189425
[TBL] [Abstract][Full Text] [Related]
9. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
[TBL] [Abstract][Full Text] [Related]
10. The Cytochrome P450 3A5 Non-Expressor Kidney Allograft as a Risk Factor for Calcineurin Inhibitor Nephrotoxicity.
Udomkarnjananun S; Townamchai N; Chariyavilaskul P; Iampenkhae K; Pongpirul K; Sirichindakul B; Panumatrassamee K; Vanichanan J; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K
Am J Nephrol; 2018; 47(3):182-190. PubMed ID: 29539600
[TBL] [Abstract][Full Text] [Related]
11. Influence of cytochrome P450 3A5 polymorphisms on viral infection incidence in kidney transplant patients treated with tacrolimus.
Hattori Y; Tanaka H; Teranishi J; Ishida H; Makiyama K; Miyajima E; Noguchi K; Kubota Y
Transplant Proc; 2014; 46(2):570-3. PubMed ID: 24656015
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
13. Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.
Chitnis SD; Ogasawara K; Schniedewind B; Gohh RY; Christians U; Akhlaghi F
Xenobiotica; 2013 Jul; 43(7):641-9. PubMed ID: 23278282
[TBL] [Abstract][Full Text] [Related]
14. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
[TBL] [Abstract][Full Text] [Related]
15. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
16. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit.
de Jonge H; Vanhove T; de Loor H; Verbeke K; Kuypers DR
Br J Clin Pharmacol; 2015 Sep; 80(3):548-59. PubMed ID: 26114223
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
19. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
[TBL] [Abstract][Full Text] [Related]
20. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.
Andrews LM; Hesselink DA; van Schaik RHN; van Gelder T; de Fijter JW; Lloberas N; Elens L; Moes DJAR; de Winter BCM
Br J Clin Pharmacol; 2019 Mar; 85(3):601-615. PubMed ID: 30552703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]